Open AccessThiophene Derivatives as New Anticancer Agents and Their Therapeutic Delivery Using Folate Receptor-Targeting Nanocarriers
Author(s) -
Menghui Zhao,
Yaxin Cui,
Lang Zhao,
Tianyu Zhu,
Robert J. Lee,
WeiWei Liao,
Fengying Sun,
Youxin Li,
Lesheng Teng
Publication year - 2019
Publication title -
acs omega
Language(s) - English
Resource type - Journals
ISSN - 2470-1343
DOI - 10.1021/acsomega.9b00554
Subject(s) - nanocarriers , hela , thiophene , cytotoxicity , flow cytometry , chemistry , folate receptor , surface modification , reactive oxygen species , apoptosis , pharmacology , combinatorial chemistry , drug delivery , ic50 , cancer cell , biochemistry , cell , cancer , in vitro , organic chemistry , microbiology and biotechnology , medicine , biology
A series of thiophene derivatives were synthesized by functionalization of 2,3-fused thiophene scaffolds. Their cytotoxicity was assessed against HeLa and Hep G2 cells. Compound 480 was identified as a promising candidate because of its low IC 50 in HeLa (12.61 μg/mL) and Hep G2 (33.42 μg/mL) cells. The drug was loaded into folic acid (FA)-coated nanoparticles (NPs) to address its poor water solubility and to improve its selectivity for cancer cells. Compound 480 was shown to induce apoptosis by changes in mitochondrial membrane potential (ΔΨ m ) and the reactive oxygen species level. Furthermore, FA-modified NPs enhanced uptake capacity compared to unmodified controls by flow cytometry. This drug delivered in folate nanocarriers is promising for the treatment of cancers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom